Edvardsen Svenn Magne sold $6.9M of DHT

DHT Holdings (DHT) stock rose 5.34% to $25.95 after reporting strong Q4 spot rates for its VLCCs at $509,100 per day, with 50% of available spot days booked. The company's Q3 fleet earnings were estimated at $141,300 per day, and Q4 earnings are estimated at $225,200 per day for 78% of revenue days.

DHT Holdings (DHT) rose 5.4% to a 52-week high of $26.47 after reporting strong Q4 bookings. Half of available spot days were booked at $509,100/day, with 78% of revenue days at $225,200/day. Q3 fleet earnings were forecast at $141,300/day, with spot VLCCs at $167,100/day and time-chartered VLCCs at $114,200/day.

DHT Holdings (DHT) rose 5.4% to a 52-week high of $26.47 after reporting strong bookings, with half of available spot days booked at an average rate of $509,100/day.

DHT Holdings (DHT) stock rose 4.3% in pre-market trading after reporting strong Q3 2026 fleet earnings, with spot VLCCs averaging $167,100/day and time-chartered vessels $114,200/day. About 50% of Q4 spot days are booked at $509,100/day. The company's shares have gained 123% YTD, reaching a new 52-week high of $26.22.

DRI Healthcare Trust (DHT.U) will acquire U.S. royalty rights for Juvmo (tavapadon) for $316M, with payments capped at $437.5M. The deal includes fixed annual payments and tiered royalties, closing expected by Sept. 29, 2026. This acquisition aligns with DRI's strategy of investing in approved therapies, adding exposure to a Parkinson's drug.

DHT Holdings (DHT) secured a three-year charter for the VLCC DHT Panther at $100,000 per day, starting October 2026. This contract improves revenue visibility and reduces earnings uncertainty. Analysts expect DHT's revenue and earnings to decline 21.2% and 27.6% annually over the next three years, respectively, but the charter may mitigate some risks.